Bristol Myers Squibb (CELG-RI) Land & Improvements (2025 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Land & Improvements of $157.0 million for Q2 2026, little changed quarter-over-quarter from $157.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Land & Improvements (2025 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Land & Improvements for 2 consecutive years, with $157.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Land & Improvements changed N/A year-over-year to $157.0 million; the TTM figure through Jun 2026 stood at $157.0 million (changed N/A YoY), while the FY2025 annual figure was $157.0 million, changed N/A from the prior year.
- Land & Improvements was little changed at $157.0 million in Q2 2026 per CELG-RI's latest filing, from $157.0 million in the prior quarter.
- Across five years, Land & Improvements topped out at $157.0 million in Q4 2025 and bottomed at $157.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 157.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 157.00 Mn |
| Mar 31, 2026 | 157.00 Mn |
| Dec 31, 2025 | 157.00 Mn |